Premium
Targeted delivery of protein and gene medicines through the blood–brain barrier
Author(s) -
Pardridge WM
Publication year - 2015
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.18
Subject(s) - blood–brain barrier , monoclonal antibody , transferrin receptor , peptidomimetic , pharmacology , recombinant dna , immunogenicity , receptor , medicine , antibody , chemistry , gene , immunology , biochemistry , central nervous system , peptide
The development of biologic drugs (recombinant proteins, therapeutic antibodies, peptides, nucleic acid therapeutics) as new treatments of brain disorders has been difficult, and a major reason is the lack of transport through the blood–brain barrier (BBB) of these large molecule pharmaceuticals. Biologic drugs can be re‐engineered as brain‐penetrating neuropharmaceuticals using BBB molecular Trojan horse technology. Certain peptidomimetic monoclonal antibodies that target endogenous receptors on the BBB, such as the insulin or transferrin receptor, enable the re‐engineering of biologic drugs that cross the BBB.